These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. In vitro activity of tigecycline against isolates from patients enrolled in phase 3 clinical trials of treatment for complicated skin and skin-structure infections and complicated intra-abdominal infections. Bradford PA; Weaver-Sands DT; Petersen PJ Clin Infect Dis; 2005 Sep; 41 Suppl 5():S315-32. PubMed ID: 16080070 [TBL] [Abstract][Full Text] [Related]
5. Establishing the role of tigecycline in an era of antimicrobial resistance. Schafer JJ; Goff DA Expert Rev Anti Infect Ther; 2008 Oct; 6(5):557-67. PubMed ID: 18847395 [TBL] [Abstract][Full Text] [Related]
6. Therapeutic applications of tigecycline in the management of complicated skin and skin structure infections. Grolman DC Int J Infect Dis; 2007 May; 11 Suppl 1():S7-15. PubMed ID: 17603950 [TBL] [Abstract][Full Text] [Related]
7. Tigecycline: the answer to beta-lactam and fluoroquinolone resistance? Fraise AP J Infect; 2006 Nov; 53(5):293-300. PubMed ID: 16876253 [TBL] [Abstract][Full Text] [Related]
8. Potency and spectrum of tigecycline tested against an international collection of bacterial pathogens associated with skin and soft tissue infections (2000-2004). Fritsche TR; Sader HS; Stilwell MG; Dowzicky MJ; Jones RN Diagn Microbiol Infect Dis; 2005 Jul; 52(3):195-201. PubMed ID: 16105564 [TBL] [Abstract][Full Text] [Related]
9. Use of in vitro susceptibility and pathogen prevalence data to model the expected clinical success rates of tigecycline and other commonly used antimicrobials for empirical treatment of complicated skin and skin-structure infections. Sader HS; Mallick R; Kuznik A; Fritsche TR; Jones RN Int J Antimicrob Agents; 2007 Dec; 30(6):514-20. PubMed ID: 17959359 [TBL] [Abstract][Full Text] [Related]
10. Serum bactericidal activities of moxifloxacin and levofloxacin against aerobic and anaerobic intra-abdominal pathogens. Stein GE; Schooley S; Tyrrell KL; Citron DM; Nicolau DP; Goldstein EJ Anaerobe; 2008 Feb; 14(1):8-12. PubMed ID: 17983770 [TBL] [Abstract][Full Text] [Related]
11. Tigecycline: a novel glycylcycline antibiotic. Zhanel GG; Karlowsky JA; Rubinstein E; Hoban DJ Expert Rev Anti Infect Ther; 2006 Feb; 4(1):9-25. PubMed ID: 16441206 [TBL] [Abstract][Full Text] [Related]
12. Tigecycline: first of a new class of antimicrobial agents. Rose WE; Rybak MJ Pharmacotherapy; 2006 Aug; 26(8):1099-110. PubMed ID: 16863487 [TBL] [Abstract][Full Text] [Related]
13. Clinical and microbiological efficacy of tigecycline for complicated skin-soft-tissue and intra-abdominal infections in a Turkish university hospital. Avkan-Oguz V; Yapar N; Alp-Cavus S; Demir Onder K; Aktas E; Gulay Z; Cakır N Int J Clin Pract; 2013 Jun; 67(6):505-11. PubMed ID: 23679904 [TBL] [Abstract][Full Text] [Related]
14. Efficacy of tigecycline for the treatment of complicated skin and soft-tissue infections in real-life clinical practice from five European observational studies. Montravers P; Bassetti M; Dupont H; Eckmann C; Heizmann WR; Guirao X; García MS; Capparella MR; Simoneau D; Bodmann KF J Antimicrob Chemother; 2013 Jul; 68 Suppl 2():ii15-24. PubMed ID: 23772042 [TBL] [Abstract][Full Text] [Related]
15. In vitro activity of tigecycline against strains isolated from diabetic foot ulcers. Sotto A; Bouziges N; Jourdan N; Richard JL; Lavigne JP Pathol Biol (Paris); 2007 Nov; 55(8-9):398-406. PubMed ID: 17905534 [TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of tigecycline monotherapy compared with vancomycin plus aztreonam in patients with complicated skin and skin structure infections: Results from a phase 3, randomized, double-blind trial. Sacchidanand S; Penn RL; Embil JM; Campos ME; Curcio D; Ellis-Grosse E; Loh E; Rose G Int J Infect Dis; 2005 Sep; 9(5):251-61. PubMed ID: 16099700 [TBL] [Abstract][Full Text] [Related]
17. The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam. Ellis-Grosse EJ; Babinchak T; Dartois N; Rose G; Loh E; ; Clin Infect Dis; 2005 Sep; 41 Suppl 5():S341-53. PubMed ID: 16080072 [TBL] [Abstract][Full Text] [Related]
18. Prescription behaviours for tigecycline in real-life clinical practice from five European observational studies. Bassetti M; Eckmann C; Bodmann KF; Dupont H; Heizmann WR; Montravers P; Guirao X; Capparella MR; Simoneau D; Sánchez García M J Antimicrob Chemother; 2013 Jul; 68 Suppl 2():ii5-14. PubMed ID: 23772047 [TBL] [Abstract][Full Text] [Related]
19. In vitro activities of tigecycline against recently isolated Gram-negative anaerobic bacteria in Greece, including metronidazole-resistant strains. Katsandri A; Avlamis A; Pantazatou A; Petrikkos GL; Legakis NJ; Papaparaskevas J; Diagn Microbiol Infect Dis; 2006 Jul; 55(3):231-6. PubMed ID: 16626904 [TBL] [Abstract][Full Text] [Related]
20. Effect of tigecycline on normal oropharyngeal and intestinal microflora. Nord CE; Sillerström E; Wahlund E Antimicrob Agents Chemother; 2006 Oct; 50(10):3375-80. PubMed ID: 17005820 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]